Suppr超能文献

纤维肌性发育不良所致肾动脉狭窄血运重建疗效的系统评价和荟萃分析。

Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis.

机构信息

Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France.

出版信息

Hypertension. 2010 Sep;56(3):525-32. doi: 10.1161/HYPERTENSIONAHA.110.152918. Epub 2010 Jul 12.

Abstract

In patients with fibromuscular dysplasia and renal artery stenosis, renal artery revascularization has been used to cure hypertension or to improve blood pressure control. To provide an up-to-date assessment of the benefits and risks associated with revascularization in this condition, we performed a systematic review of studies in which hypertensive patients with fibromuscular dysplasia renal artery stenosis underwent percutaneous transluminal renal angioplasty or surgical reconstruction. We assessed how often periprocedural complications and hypertension cure and improvement occurred. We selected 47 angioplasty studies (1616 patients) and 23 surgery studies (1014 patients). Combined rates of hypertension cure, defined according to the criteria in each study, after angioplasty or surgery were estimated to be 46% (95% CI: 40% to 52%) and 58% (95% CI: 53% to 62%), respectively, with substantial variations across studies. The probability of being cured was negatively associated with patient age and time of publication. Cure rates using current definitions of hypertension cure (blood pressure <140/90 mm Hg without treatment) were only 36% and 54% after angioplasty and surgery, respectively. The combined risks of periprocedural complications were 12% and 17% after angioplasty and surgery, respectively, with less major complications after angioplasty than surgery (6% versus 15%). In conclusion, angioplasty or surgical revascularization yielded moderate benefits in patients with fibromuscular dysplasia renal artery stenosis, with substantial variation across studies. The blood pressure outcome was strongly influenced by patient age.

摘要

在纤维肌性发育不良和肾动脉狭窄的患者中,肾动脉血运重建术已被用于治疗高血压或改善血压控制。为了对该情况下血运重建术的获益和风险提供最新评估,我们对接受经皮腔内肾血管成形术或手术重建的纤维肌性发育不良肾动脉狭窄的高血压患者的研究进行了系统评价。我们评估了围手术期并发症以及高血压治愈和改善的发生频率。我们选择了 47 项经皮腔内肾血管成形术研究(1616 例患者)和 23 项手术研究(1014 例患者)。根据每项研究的标准,经皮腔内肾血管成形术或手术治疗后,高血压治愈(定义为根据每项研究的标准治愈的高血压患者比例)的综合发生率估计分别为 46%(95%CI:40%至 52%)和 58%(95%CI:53%至 62%),研究之间存在很大差异。被治愈的概率与患者年龄和发表时间呈负相关。使用目前高血压治愈的定义(未经治疗的血压<140/90mmHg),经皮腔内肾血管成形术和手术治疗后的治愈率分别仅为 36%和 54%。经皮腔内肾血管成形术和手术治疗后,围手术期并发症的综合风险分别为 12%和 17%,经皮腔内肾血管成形术的主要并发症发生率低于手术(6%对 15%)。总之,纤维肌性发育不良肾动脉狭窄患者经皮腔内肾血管成形术或手术血运重建术的获益中等,研究之间存在很大差异。血压结果受患者年龄的强烈影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验